

Brooks Adams, MBA

Executive Director and President, North Carolina Center of Innovation for Nanobiotechnology



Mr. Adams has worked for 14 years in innovation management in the life sciences, including in biotechnology, specialty pharmaceuticals/drug delivery, and genomics. During this time, he held leadership roles in global business development and marketing with both major multinational and entrepreneurial startup firms. Mr. Adams has experience with new market/opportunity identification and assessment in formulating and implementing growth strategies, and in successfully negotiating, structuring, and closing business development transactions in support of new technology-based products. Mr. Adams has worked on several significant projects involving the commercialization of nano and microscale technologies, including nano-aerosols for drug delivery, gene arrays, and DNA diagnostics.

James C. Oliver, Pharm.D.

President and CEO, Peptagen, Inc. and Trinity Drug Partners, L.L.C.



Dr. Oliver has more than 25 years of industry experience, including roles as CEO, COO, CSO, and Medical Officer with both public and private companies. Most recently, Dr. Oliver was responsible for the clinical and manufacturing (CMC) program around a nanoparticle cancer therapeutic under an U.S. IND. His oversight included design and execution of phase 1 dose-escalation studies and initiation of a phase 2 study in ovarian cancer. In addition, Jamie has provided ongoing consulting advice expertise in areas of therapeutic nanoparticle formulation and development. Dr. Oliver has participated in Face to Face meetings with more than half of the 18 review Divisions of the OND at FDA. He has authored multiple successful 505 (b)(2) Pre-IND and IND submissions, represented and attended FDA meetings for all types of PDUFA meetings; (Type A, Type B, Pre-IND, End of Phase 2, Pre-NDA, SPA). Dr. Oliver's academic tenure includes adjunct faculty collaboration with Emory University, Mercer University, and the Centers for Disease Control and Prevention Epidemiology Investigations Branch.

Robert Susick, Ph.D.  
President and CEO, NanIO Biosciences



Dr. Susick has 30 years of experience in pharmaceutical research and development and preclinical safety assessment. He has worked with pharmaceutical companies such as Eli Lilly and Parke-Davis, biotech companies Sphinx Pharmaceuticals and Incara Pharmaceuticals, and the drug development consulting company Fulcrum Pharma Developments. Susick earned his doctorate in toxicology at the University of Michigan and is a Diplomat of the American Board of Toxicology.

John W. Ludlow, Ph.D.  
Senior Director, Process Research and Assay Development



Dr. Ludlow joined Tengion Inc. in 2005 and is currently the Senior Director of Process Research and Assay Development. After spending 10 years conducting tumor suppressor research at the University of Rochester Cancer Center, Dr. Ludlow went on to become Director of the Cell Therapy Program for Incara Pharmaceuticals, and then Senior Director of the Cell Therapy Program at Vesta Therapeutics. Not only has he developed and managed research and pre-clinical programs, initiated clinical trial sites, and directed development activities for cell therapy and tissue engineered products, but Dr. Ludlow has also worked closely with regulatory agencies to help ensure approval of the company's products. He is an inventor on one patent awarded in 2008, and is on the inventor list of six currently filed patent applications. He specializes in laboratory-based research and development of cell and tissue engineered products for regenerative medicine applications.